34 reports

Bile acid sequestrates lead to side effects related to the gastrointestinal tract.

  • Cardiovascular Disease
  • Cholesterol
  • Lipid Modifying Drug
  • Statins
  • AstraZeneca PLC

GASTROINTESTINAL SIDE EFFECTS WERE THE MOST COMMON AND INCLUDED ERUCTATION, DIARRHEA, AND NAUSEA.

  • Cholesterol
  • AstraZeneca PLC
  • Cerenis
  • Merck & Co., Inc.
  • The Medicines Company

GASTROINTESTINAL SIDE EFFECTS WERE THE MOST COMMON AND INCLUDED ERUCTATION, DIARRHEA, AND NAUSEA.

  • Cholesterol
  • World
  • AstraZeneca PLC
  • Merck & Co., Inc.
  • Pfizer Inc.

GASTROINTESTINAL SIDE EFFECTS WERE THE MOST COMMON AND INCLUDED ERUCTATION, DIARRHEA, AND NAUSEA.

  • Cholesterol
  • World
  • AstraZeneca PLC
  • Merck & Co., Inc.
  • Pfizer Inc.

GASTROINTESTINAL SIDE EFFECTS WERE THE MOST COMMON AND INCLUDED ERUCTATION, DIARRHEA, AND NAUSEA.

  • Cholesterol
  • World
  • AstraZeneca PLC
  • Merck & Co., Inc.
  • Pfizer Inc.

GASTROINTESTINAL SIDE EFFECTS WERE THE MOST COMMON AND INCLUDED ERUCTATION, DIARRHEA, AND NAUSEA.

  • Cholesterol
  • World
  • AstraZeneca PLC
  • Merck & Co., Inc.
  • Pfizer Inc.

GASTROINTESTINAL GLUCOSE-LOWERING EFFECT OF WELCHOL STUDY GENERAL PRACTITIONER GLAXOSMITHKLINE FIRST HALF; H##: SECOND HALF GLYCOSYLATED HEMOGLOBIN HIGH-DENSITY LIPOPROTEIN HIGH-DENSITY LIPOPROTEIN CHOLESTEROL HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA HUMAN IMMUNODEFICIENCY VIRUS HOMOZYGOUS

  • Cholesterol
  • AstraZeneca PLC
  • GlaxoSmithKline plc
  • Merck & Co., Inc.
  • Pfizer Inc.
  • DYSLIPIDEMIA - PIPELINE BY JENRIN DISCOVERY INC, H1 2017
  • DYSLIPIDEMIA - PIPELINE BY JW PHARMACEUTICAL CORP, H1 2017

The company offers over-the-counter products for pain relief, oral health, nutrition, skin health and gastrointestinal disorders.

  • Cholesterol
  • Obesity
  • Pharmaceutical
  • Statins
  • Esperion Therapeutics, Inc.
  • HS-25 - Drug Profile

It is found on the gastrointestinal tract epithelial cells as well as in hepatocytes.

  • Cholesterol
  • Lipid Modifying Drug
  • United States
  • Product Initiative
  • Merck & Co., Inc.
  • Phase II - Trial Details
  • R&D Progress Research and Development Brief

It is found on the gastrointestinal tract epithelial cells as well as in hepatocytes.

  • Cholesterol
  • South Korea
  • United States
  • World
  • Product Initiative

The company' s products are used in the treatment of cancer, depression, dementia, dermatology, diabetes, anti-inflammatory, cardiovascular, epilepsy, hepatitis, hypnotics, osteoarthritis, gastrointestinal, osteoporosis and others.

  • Cholesterol
  • South Korea
  • United States
  • World
  • Product Initiative
  • Aug 11, 2017: Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
  • Clinical Trials

Inhibition of Niemann-Pick C##-Like ## (NPC##L##) by ezetimibe results in reduced absorption of cholesterol from the gastrointestinal tract, thereby reducing delivery of cholesterol to the liver, which in turn upregulates LDL receptors.

  • Cholesterol
  • Lipid Modifying Drug
  • Therapy
  • United States
  • Esperion Therapeutics, Inc.

Gastrointestinal ## ## Source: Global Markets Direct Therapy Area Company Universities/ Institutes Number of Products under Development by Top ## Indication, H## 2016 Oxysterols Receptor LXR Beta (Liver X Receptor Beta or Nuclear Receptor NER or Nuclear Receptor Subfamily ## Group H Member

  • Antimalarials
  • Cholesterol
  • United States
  • Product Initiative
  • Vitae Pharmaceuticals, Inc.
  • Number of Products under Development by Therapy Area, H2 2016

It focuses on the research and development, manufacture, and sale of medicines for the treatment of cancer, cardiovascular diseases, central nervous system disorders, ophthalmic diseases, gastrointestinal and respiratory diseases, infectious diseases, dermatological conditions and allergies

  • Cholesterol
  • United States
  • Company
  • Product Initiative
  • Galmed Pharmaceuticals Ltd.

It offers products for the treatment of respiratory, cardiovascular and metabolic diseases and conditions, infection, inflammation, cancer, ophthalmic diseases, neurological problems, pain, tissue repair, gastrointestinal diseases, women' s health issues, orphan diseases and genitourina

  • Cardiovascular Disease
  • Cholesterol
  • United States
  • World
  • Product Initiative

Gastrointestinal ## ## Central Nervous System ## ## Source: Global Markets Direct Therapy Area Company Universities/ Institutes APOLIPOPROTEIN E (APOE) - PRODUCTS UNDER DEVELOPMENT BY INDICATION NUMBER OF PRODUCTS UNDER DEVELOPMENT BY TOP ## INDICATION, H## 2016 NUMBER OF PRODUCTS UNDER DEVE

  • Cardiovascular Disease
  • Cholesterol
  • United States
  • Product Initiative
  • LipimetiX Development LLC

This report is a licensed product and is not to be photocopied Cerenis Therapeutics Holding SA - Research and Development Overview Cerenis Therapeutics Holding SA has promising clinical drug candidates for ## major therapeutic areas, Cardiovascular, Gastrointestinal, Immunology and Metabolic

  • Cholesterol
  • Therapy
  • World
  • Product Initiative
  • Cerenis
  • Number of Products under Development by Therapy Area, H1 2016

It focuses on the research and development, manufacture, and sale of medicines for the treatment of cancer, cardiovascular diseases, central nervous system disorders, ophthalmic diseases, gastrointestinal and respiratory diseases, infectious diseases, dermatological conditions and allergies

  • Cholesterol
  • United States
  • Company
  • Product Initiative
  • Galmed Pharmaceuticals Ltd.

- Research and Development Overview Jenrin Discovery, Inc. has promising clinical drug candidates for ## major therapeutic areas, Cardiovascular, Gastrointestinal, Infectious Disease, Oncology, Immunology and Metabolic Disorders.

  • Analgesic
  • Cholesterol
  • Obesity
  • Research And Development
  • Jenrin Discovery, Inc.

Gastrointestinal ## ## Central Nervous System ## ## APOLIPOPROTEIN E (APOE) - PRODUCTS UNDER DEVELOPMENT BY INDICATION NUMBER OF PRODUCTS UNDER DEVELOPMENT BY TOP ## INDICATION, H## 2016 NUMBER OF PRODUCTS UNDER DEVELOPMENT BY INDICATION, H## 2016 COMPARATIVE ANALYSIS BY LATE STAGE DEVELOPMENT, H

  • Cardiovascular Disease
  • Cholesterol
  • United States
  • Product Initiative
  • LipimetiX Development LLC
  • DYSLIPIDEMIA - PIPELINE BY JW PHARMACEUTICAL CORP, H2 2017
  • DYSLIPIDEMIA - PIPELINE BY KOTOBUKI PHARMACEUTICAL CO LTD, H2 2017

The company offers products for cardiovascular, gastrointestinal, nephrology or antianaemic, anticancer and neuropsychiatry.

  • Cholesterol
  • Chronic Disease
  • United States
  • World
  • Product Initiative
  • MIXED DYSLIPIDEMIA - PIPELINE BY HANMI PHARMACEUTICALS, CO. LTD., H1 2016
  • MIXED DYSLIPIDEMIA - PIPELINE BY PFIZER INC., H1 2016

The company' s products are used in the treatment of cancer, depression, dementia, dermatology, diabetes, anti-inflammatory, cardiovascular, epilepsy, hepatitis, hypnotics, osteoarthritis, gastrointestinal, osteoporosis and others.

  • Cholesterol
  • Lipid Modifying Drug
  • United States
  • Product Initiative
  • Amgen Inc.

Growth in molecular biology lines was driven by the ongoing fast-paced development of FilmArray®, and in particular the Gastrointestinal and Meningitis/ Encephalitis panels.

  • Cholesterol
  • Clinical Trial
  • Infectious Disease
  • United States
  • GlobalData's company
  • Clinical Trial profile. 1413 Trial Title
  • 5. ALL THE TRIALS INCLUDED ARE UNIQUE TRIALS.

Gastrointestinal Behavior of Simvastatin in Healthy Volunteers Gastrointestinal Behavior of Simvastatin in Healthy Volunteers GDCT## EudraCT-2013-##-##, FTB##-SMV##; s## Metabolic Disorders Hyperlipidemia Ongoing, recruiting Phase IV Interventional simvastatin University

  • Cardiovascular Disease
  • Cholesterol
  • Lipid Modifying Drug
  • Pharmaceutical
  • World

BUTYRIC ACID HAS A PROLIFERATIVE EFFECT ON MUCOSAL CELLS IN THE INTESTINE AND PROTECTS THE GASTROINTESTINAL TRACT.

  • Cholesterol
  • Digestive System Disorder
  • Pharmaceutical
  • United States
  • Product Initiative

Mild-to-moderate gastrointestinal adverse events have been the most commonly reported side effect in this trial.

  • Cholesterol
  • Therapy
  • United States
  • Product Initiative
  • Aegerion Pharmaceuticals, Inc.

This report is a licensed product and is not to be photocopied AURASENSE THERAPEUTICS, LLC - RESEARCH AND DEVELOPMENT OVERVIEW AuraSense Therapeutics, LLC has promising clinical drug candidates for ## major therapeutic areas, Cardiovascular, Gastrointestinal, Oncology, Immunology and Metabol

  • Cholesterol
  • Chad
  • World
  • Product Initiative
  • AuraSense Therapeutics LLC

Gastrointestinal Cancers Symposium 2011 (ASCO-GI 2011) on January ##, 2011 in San Francisco, US.

  • Cholesterol
  • Therapy
  • World
  • Product Initiative
  • Kowa Co., Ltd.
  • Clinical Trial profile. 567 Trial Title
  • Clinical Trial Profile Snapshots

Gastrointestinal Tumor, Inflammatory Bowel Disease, Insulin Resistance, Leukemias, Lung Cancer, Myeloproliferative Disorders, Non-Alcoholic Steatohepatitis, Pancreatic Cancer, Prostate Cancer, Type ## Diabetes Completed Phase I Interventional elafibranor Genfit SA Cardiabase Europe ## Feb ##

  • Cardiovascular Disease
  • Cholesterol
  • Clinical Trial
  • World
  • Merck & Co., Inc.

SYMPTOMS INCLUDE GASTROINTESTINAL PAIN, DIFFICULTY BREATHING, MEMORY LOSS, DEMENTIA, XANTHELASMAS AND CORNEAL ARCUS.

  • Cholesterol
  • Hospital
  • Pharmaceutical
  • United States
  • Product Initiative